Edg­ing to­ward a piv­otal read­out, Bio­gen picks a new dis­cov­ery part­ner for oph­thalmic gene ther­a­py

Al­most two years af­ter Bio­gen swooped again in­to the oph­thalmic gene ther­a­py field with an $800 mil­lion buy­out of eye-fo­cused Night­star Ther­a­peu­tics, it’s turn­ing to a young play­er for a new pro­gram.

Ger­many’s Vi­Gen­eron will be de­ploy­ing its next-gen­er­a­tion AAV vec­tors to gen­er­ate can­di­dates for a tar­get — Bio­gen isn’t dis­clos­ing which ex­act­ly — that would treat in­her­it­ed eye dis­ease. The big biotech part­ner has an­oth­er tar­get in mind, for which it has the op­tion to add with­in two years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.